Please assess the completion status of the following clinical trial:

Trial Title: AuraGain and iGel Crossover Comparison

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have read and understood patient information leaflets about the study and undergo informed consent.~* patients whose anaesthesia management is being carried out by one of the named investigators~* adult (age \>18 years) patients undergoing general anaesthesia~* American Society of Anaesthesiology Grading (ASA) 1-3~* suitability for general anaesthesia using a laryngeal mask airway device~Exclusion Criteria;~* the presence of significant acute or chronic lung disease~* pathology of neck or upper respiratory tract~* an identified or anticipated difficult intubation~* an increased risk of aspiration (hiatus hernia, gastro-oesophageal reflux or full stomach etc.) pregnant women~* a body mass index greater than 35kg.m-2~* patients unable to communicate fully in English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- i-Gel and AuraGain (Type: ACTIVE_COMPARATOR): In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma
- AuraGain and i-Gel (Type: ACTIVE_COMPARATOR): In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~1. Insertion of the laryngeal mask airway~2. Assessment of ease of insertion~3. Ability to perform positive pressure ventilation~4. Measurement of OLP~5. Fibreoptic assessment with Ambu A-scope~6. Ability to insert nasogastric tube~7. Record number of manipulations~8. An assessment of device related trauma

Based on this trial design, predict the completion outcome and termination type (if applicable).